Featured Research

from universities, journals, and other organizations

Certain new therapies for age-related eye disease do not appear to increase heart risks

Date:
October 11, 2010
Source:
JAMA and Archives Journals
Summary:
Newer treatments for age-related macular degeneration -- including an intravitreous (into the eye) injection of a chemotherapy drug and use of a related compound approved for use against the eye disease -- do not appear to be associated with an increased risk of cardiovascular complications or death when compared with existing therapies, according to a new study.

Newer treatments for age-related macular degeneration (AMD) -- including an intravitreous (into the eye) injection of a chemotherapy drug and use of a related compound approved for use against the eye disease -- do not appear to be associated with an increased risk of cardiovascular complications or death when compared with existing therapies, according to a report in the October issue of Archives of Ophthalmology, one of the JAMA/Archives journals.

"More than 1.5 million older Americans have age-related macular degeneration, the most common cause of irreversible vision loss among older patients," the authors write as background information in the article. Of these, 12 percent have neovascular disease, which occurs when new blood vessels form in the eye and accounts for more than 80 percent of cases of severe vision loss. Before June 2006, there were two approved therapies for this condition, both of which slow vision loss but usually do not improve visual acuity: photodynamic (laser) therapy in combination with the photosensitizing medication verteporfin, and eye injections with pegaptanib octasodium, a nucleic blocking abnormal blood vessel growth.

By the fall of 2005, ophthalmologists began treating AMD with the cancer drug bevacizumab, an antibody that also blocks blood vessel growth. In June 2006, ranibizumab -- an antibody fragment with a similar mechanism -- was approved by the Food and Drug Administration for treatment of AMD. "In chemotherapy regimens, bevacizumab is associated with an increased risk of thromboembolic events," when a blood clot forms and travels through blood vessels, potentially causing a stroke or heart attack, the authors write. "However, intravitreous bevacizumab is administered at a dose of 1 to 2.5 milligrams, 150 times less than the systemic dose. Despite the regulatory approval of ranibizumab, off-label use of bevacizumab continues, likely because of the cost difference ($1,950 per dose of ranibizumab vs. $30 per dose of bevacizumab. The relatively safety of the therapies is unknown."

Lesley H. Curtis, Ph.D., and colleagues at Duke University School of Medicine, Durham, N.C., and colleagues analyzed records from 146,942 Medicare beneficiaries who received treatment for AMD in 2005 or 2006. Reports of deaths, heart attacks, bleeding and stroke were tracked through 2007.

There were no differences in the risk of death or heart attack between the bevacizumab group and any other therapy group, and bleeding events or stroke did not differ by treatment group. Patients who received ranibizumab therapy were less likely to die or have a heart attack than those who received photodynamic therapy and less likely to have a heart attack than those given pegaptanib. The authors note that there is no evidence that photodynamic therapy and pegaptanib use is associated with increased risks of adverse systemic effects, so the differences may suggest residual confounding.

"In conclusion, we found no evidence of increased risks of mortality, myocardial infarction, bleeding or stroke among Medicare beneficiaries who received intravitreous ranibizumab or bevacizumab for neovascular age-related macular degeneration," the authors write.


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Journal Reference:

  1. L. H. Curtis, B. G. Hammill, K. A. Schulman, S. W. Cousins. Risks of Mortality, Myocardial Infarction, Bleeding, and Stroke Associated With Therapies for Age-Related Macular Degeneration. Archives of Ophthalmology, 2010; 128 (10): 1273 DOI: 10.1001/archophthalmol.2010.223

Cite This Page:

JAMA and Archives Journals. "Certain new therapies for age-related eye disease do not appear to increase heart risks." ScienceDaily. ScienceDaily, 11 October 2010. <www.sciencedaily.com/releases/2010/10/101011173447.htm>.
JAMA and Archives Journals. (2010, October 11). Certain new therapies for age-related eye disease do not appear to increase heart risks. ScienceDaily. Retrieved September 23, 2014 from www.sciencedaily.com/releases/2010/10/101011173447.htm
JAMA and Archives Journals. "Certain new therapies for age-related eye disease do not appear to increase heart risks." ScienceDaily. www.sciencedaily.com/releases/2010/10/101011173447.htm (accessed September 23, 2014).

Share This



More Health & Medicine News

Tuesday, September 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Liberia Pleads for Help to Fight Ebola

Liberia Pleads for Help to Fight Ebola

AP (Sep. 22, 2014) Liberia's finance minister is urging the international community to quickly follow through on pledges of cash to battle Ebola. Bodies are piling up in the capital Monrovia as the nation awaits more help. (Sept. 22) Video provided by AP
Powered by NewsLook.com
Ebola Doctor Says Border Controls Critical

Ebola Doctor Says Border Controls Critical

AP (Sep. 22, 2014) A Florida doctor who helped fight the expanding Ebola outbreak in West Africa says the disease can be stopped, but only if nations quickly step up their response and make border control a priority. (Sept. 22) Video provided by AP
Powered by NewsLook.com
Global Ebola Aid Increasing But Critics Say It's Late

Global Ebola Aid Increasing But Critics Say It's Late

Newsy (Sep. 21, 2014) More than 100 tons of medical supplies were sent to West Africa on Saturday, but aid workers say the global response is still sluggish. Video provided by Newsy
Powered by NewsLook.com
Sierra Leone in Lockdown to Control Ebola

Sierra Leone in Lockdown to Control Ebola

AP (Sep. 21, 2014) Sierra Leone residents remained in lockdown on Saturday as part of a massive effort to confine millions of people to their homes in a bid to stem the biggest Ebola outbreak in history. (Sept. 20) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins